Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Case Study
  • Published:

Liquid refreshment

Nature Biotechnology volume 31, page 115 (2013)Cite this article

Subjects

Compared with the long time horizons and diminished returns of traditional antibody startups, Ablexis gave investors a deal they couldn't refuse.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Anonymous. Monoclonal Antibodies: 2010 <http://www.datamonitor.com/store/Product/monoclonal_antibodies_2010?productid=HC00029-002> (Datamonitor, 2010).

  2. DiMasi, J. et al. Clin. Pharmacol. Ther. 87, 272–277 (2010).

    Article  CAS  Google Scholar 

Download references

Author information

Author notes

  1. Christopher Scott is Contributing Editor at Nature Biotechnology.

Authors
  1. Christopher Scott
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Scott, C. Liquid refreshment. Nat Biotechnol 31, 115 (2013). https://doi.org/10.1038/nbt.2481

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nbt.2481

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing